Immunomodulatory Nanomedicine

Bartneck, Matthias

doi:10.1002/mabi.201700021

Cited by 12 publications

(13 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[9,10] As a result, it may be beneficial to develop carrier systems for delivering peptide antigens to immune cells. [11] To improve the biological performance of www.advancedsciencenews.com www.mbs-journal.de optimization of peptide and adjuvant incorporation and lymph targeting has not been reported.…”

Section: Doi: 101002/mabi201800301mentioning

confidence: 99%

“…Despite the promising potential of peptides as antigens for cancer vaccines, several concerns regarding peptide antigens, including poor antigen presentation, low immunopotency, and a short half‐life in vivo, have hampered their clinical translation . As a result, it may be beneficial to develop carrier systems for delivering peptide antigens to immune cells . To improve the biological performance of peptide antigens as cancer vaccines, biomaterials such as nanoparticles, microparticles, and hydrogels have been used to encapsulate peptides .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Efficient Delivery of Tyrosinase Related Protein‐2 (TRP2) Peptides to Lymph Nodes using Serum‐Derived Exosomes

Park

Choi

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

Exosomes (EXO) are considered to be versatile carriers for biomolecules; however, the delivery of therapeutic peptides using EXOs poses several challenges. In this study, the efficiency of serum‐derived EXOs in delivering tyrosinase‐related protein‐2 (TRP2) peptides to lymph nodes is determined. TRP2 peptides are successfully incorporated into EXOs, which show a uniform and narrow size distribution of around 45 nm. The TRP2‐incorporated exosomes (EXO‐TRP2) are efficiently internalized into macrophages and dendritic cells, and are seen to display a punctate distribution. EXOs loaded with TRP2 together with MPLA, (EXO‐MPLA‐TRP2) result in a strong release of proinflammatory cytokines (TNF‐α and IL‐6) from both RAW264.7 and DC2.4 cells. Finally, subcutaneous injection of fluorescently labeled EXO‐TRP2 followed by ex vivo imaging using in vivo imaging system (IVIS) show a strong fluorescent signal in the lymph nodes after only 1 h, which is maintained until at least 4 h after injection. Taken together, the findings suggest that serum‐derived EXOs can serve as promising carriers to deliver therapeutic peptides to lymph nodes for immunotherapy.

show abstract

Section: Doi: 101002/mabi201800301mentioning

confidence: 99%

mentioning

confidence: 99%

Efficient Delivery of Tyrosinase Related Protein‐2 (TRP2) Peptides to Lymph Nodes using Serum‐Derived Exosomes

Park

Choi

et al. 2018

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…The transmigration of neutrophils to sites of inflammation is guided by adhesion molecules which function as molecular traffic signs (108). These molecules are represented most prominently by selectins and integrins.…”

Section: Introductionmentioning

confidence: 99%

“…NM also enable to combine several features in a single carrier. For instance, the NM surface can be equipped with a ligand for cell receptors which serves as a targeting vector whereas the core can be loaded with a drug, allowing for selective delivery of tailored drugs (108). This specific drug targeting, i.e., by using a ligand specific for a certain receptor, is referred to as “active targeting.” Albumin and lipid-based NM belong, in terms of market value, to the most successful types of NM formulation.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Targeting of Neutrophil Granulocytes in Inflammatory Liver Disease

Bartneck

Wang

2019

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Neutrophil granulocytes are the most numerous type of leukocyte in humans bearing an enormous, yet largely unexplored therapeutic potential. Scientists have very recently increased their efforts to study and understand these cells which contribute to various types of inflammatory diseases and cancer. The mechanisms that regulate neutrophil recruitment to inflamed tissues and neutrophil cytotoxic activities against host tissues and pathogens require more attention. The reactive oxygen species (ROS) are a popular source of cellular stress and organ injury, and are critically expressed by neutrophils. By combating pathogens using molecular combat factors such as neutrophil extracellular traps (NETs), these are immobilized and killed i.e., by ROS. NETs and ROS are essential for the immune defense, but upon excessive activation, may also harm healthy tissue. Thus, exploring new routes for modulating their migration and activation is highly desired for creating novel anti-inflammatory treatment options. Leukocyte transmigration represents a key process for inflammatory cell infiltration to injury sites. In this review, we briefly summarize the differentiation and roles of neutrophils, with a spotlight on intravital imaging. We further discuss the potential of nanomedicines, i.e., selectin mimetics to target cell migration and influence liver disease outcome in animal models. Novel perspectives further arise from formulations of the wide array of options of small non-coding RNA such as small interfering RNA (siRNA) and micro-RNA (miR) which exhibit enzymatic functions: while siRNA binds and degrades a single mRNA based on full complementarity of binding, miR can up and down-regulate multiple targets in gene transcription and translation, mediated by partial complementarity of binding. Notably, miR is known to regulate at least 60% of the protein-coding genes and thus includes a potent strategy for a large number of targets in neutrophils. Nanomedicines can combine properties of different drugs in a single formulation, i.e., combining surface functionalization with ligands and drug delivery. Inevitably, nanomedicines accumulate in other phagocytes, a fact that should be controlled for every novel formulation to restrain activation of macrophages or modifications of the immunological synapse. Controlled drug release enabled by nanotechnological delivery systems may advance the options of modulating neutrophil activation and migration.

show abstract

“…In this respect, Matthias Bartneck provides a comprehensive overview on “Immunomodulatory Nanomedicine”. His article includes an overview on major immune cell types and their role in different diseases, selected therapeutic interventions as well as a critical perspective on novel developments in polymer‐based immune therapies …”

mentioning

confidence: 99%